Location: Phoenix Convention Center, West Building, Ballroom 301a, 300 Level
Presidential Address
ASHP President Linda S. Tyler, PharmD, FASHP, Professor (Clinical) of Pharmacotherapy at the University of Utah College of Pharmacy
Acknowledgment of the 2022 Harvey A.K. Whitney Lecture Award Recipient
Patricia C. Kienle, RPh, MPA, BCSCP, FASHP, Director of Accreditation and Medication Safety, Cardinal Health
Acknowledgment of the 2022 ASHP Chief Executive Officer’s Award for Courageous Service
The CEO’s Award for Courageous Service recognizes individuals or groups of individuals who go beyond the call of duty to serve patients or assist pharmacists in serving patients, such as under emergency conditions or in times of natural disaster or other catastrophic events.
A Conversation with Scott Gottlieb
Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He serves on the boards of Pfizer Inc. and Illumina, Inc., is a resident fellow at the American Enterprise Institute, and is a partner at the venture capital firm New Enterprise Associates.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe, and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements to post-market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and is a regular contributor to CNBC. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. In 2018, 2019, and then again in 2020 Modern Healthcare named Dr. Gottlieb the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named him one of its “50 People Transforming Healthcare in 2018.” Dr. Gottlieb is also the author of the New York Times Bestseller Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic.
Dr. Gottlieb was a practicing hospitalist and he is an elected member of the National Academy of Medicine. He lives in Westport, Connecticut with his wife and three daughters.
